More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.65B
EPS
0.77
P/E ratio
17.7
Price to sales
0.59
Dividend yield
0.576%
Beta
1.540472
Previous close
$13.90
Today's open
$13.90
Day's range
$13.89 - $13.91
52 week range
$5.69 - $13.91
show more
CEO
Joseph Morrissey
Employees
10000
Headquarters
Jersey City, NJ
Exchange
New York Stock Exchange
Shares outstanding
262621584
Issue type
Common Stock
Healthcare
Pharmaceuticals
Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI
JERSEY CITY, N.J.--(BUSINESS WIRE)--ACAAI- new pooled post-hoc analysis of VTAMA (tapinarof) cream, 1% demonstrates consistent response for atopic dermatitis disease severity and itch.
Business Wire • Nov 12, 2026

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Investment Research • Nov 10, 2026

Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1% at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon VTAMA (tapinarof) cream, 1%, new pooled post-hoc analysis of Phase 3 data will be presented at 2026 ACAAI Scientific Meeting.
Business Wire • Nov 5, 2026

Organon Announces Quarterly Dividend
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Announces Quarterly Dividend.
Business Wire • Oct 30, 2026

Organon (OGN) Q3 Earnings and Revenues Top Estimates
Organon (OGN) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.01 per share a year ago.
Zacks Investment Research • Oct 30, 2026

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • Oct 26, 2026

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.
Business Wire • Oct 19, 2026

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
Business Wire • Oct 16, 2026

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research • Oct 14, 2026

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks Investment Research • Oct 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Organon & Co. commission-free¹. Build wealth for the long term using automated trading and transfers.